Home

MRKR

(MRKR)

NCM – Real Time Price. Currency in USD

1.30

-0.05 (-3.70%)

At close: Mar 27, 2026, 4:00 PM EDT

1.30

0.00 (0.00%)

After-hours: Mar 27, 2026, 4:10 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Instagram
Telegram
LinkedIn

Home
Markets
Screener
News
About

MRKR - Marker Therapeutics, Inc. Latest News | Finranks

Home

MRKR

(MRKR)

NCM – Real Time Price. Currency in USD

1.30

-0.05 (-3.70%)

At close: Mar 27, 2026, 4:00 PM EDT

1.30

0.00 (0.00%)

After-hours: Mar 27, 2026, 4:10 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Videos

No Data

There is no data to display

Press releases

18.03.2026

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses

05.01.2026

Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with pancreatic cancer in Arm A of the clinical study

14.11.2025

Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma

05.11.2025

Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Kathryn Penkus Corzo, R.Ph., MBA to the Company's Board of Directors, effective November 1, 2025.

(MRKR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

(MRKR)

Videos

No Data

Press releases

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors